# Eli Lilly’s value share in the GLP-1 segment declined to about 56% in March.

*business · news · 2026-04-09 · Business Today*

## Key points

- Semaglutide generics launched after March 2026 patent expiry are eroding Eli Lilly's Mounjaro market share.
- Eli Lilly's value share in the GLP-1 segment dropped to 56% in March 2026.
- Over 25 semaglutide brands from more than a dozen companies have entered the Indian market.
- Novo Nordisk cut Ozempic and Wegovy starting dose prices by up to 48% in early 2026.
- Industry estimates suggest semaglutide unit sales could double or triple within a month of generics' launch.

**Companies:** Eli Lilly, Novo Nordisk, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories, Zydus Lifesciences
**Countries:** India, Denmark

[Read the full story on Business Today](https://www.businesstoday.in/industry/pharma/story/eli-lillys-mounjaro-faces-pressure-as-semaglutide-generics-gain-ground-in-india-524831-2026-04-09)

---

Canonical: https://newsio.io/n/bcf51f51-eb24-440a-9a45-84e04fe3b072/eli-lillys-value-share-in-the-glp-1-segment-declined-to-about-56-in-march
Summarized by Newsio from Business Today. https://newsio.io/how-it-works